产时阿奇霉素与安慰剂对新生儿脓毒症和死亡的影响:一项随机临床试验
该双盲、安慰剂对照随机临床试验在西非冈比亚和布基纳法索的10家卫生机构纳入11983名分娩者,随机接受产时口服阿奇霉素2 g或安慰剂。结果显示两组新生儿脓毒症或死亡复合终点发生率相似(2.0% vs 1.9%;RD 0.09,95%CI -0.39至0.57),阿奇霉素未降低新生儿脓毒症或死亡,结果不支持常规产时口服阿奇霉素用于该目的。
要点
- 产时口服阿奇霉素2 g未降低新生儿脓毒症或死亡复合终点(2.0% vs 1.9%;RD 0.09,95%CI -0.39至0.57)。
- 阿奇霉素组新生儿皮肤感染(0.8% vs 1.7%)和抗生素使用(6.2% vs 7.8%)发生率低于安慰剂组。
- 阿奇霉素组产妇乳腺炎(0.3% vs 0.5%)和产褥热(0.1% vs 0.3%)发生率低于安慰剂组。
核心结论
- 产时口服阿奇霉素未降低新生儿脓毒症或死亡率,结果不支持常规产时口服阿奇霉素用于该目的。
研究设计与样本
- 双盲、安慰剂对照随机临床试验,于2017年10月至2021年5月在西非冈比亚和布基纳法索的10家卫生机构纳入并随访分娩者及其婴儿。
- 共随机11983名分娩者(中位年龄29.9岁),按1:1随机接受产时口服阿奇霉素2 g或安慰剂。
主要发现
- 主要复合终点新生儿脓毒症或死亡发生率:阿奇霉素组2.0%(115/5889)vs 安慰剂组1.9%(110/5894);RD 0.09(95%CI -0.39至0.57)。
- 新生儿死亡率:阿奇霉素组0.8% vs 安慰剂组0.8%;RD 0.04(95%CI -0.27至0.35)。
- 新生儿脓毒症发生率:阿奇霉素组1.3% vs 安慰剂组1.3%;RD 0.02(95%CI -0.38至0.43)。
- 新生儿皮肤感染发生率:阿奇霉素组0.8% vs 安慰剂组1.7%;RD -0.90(95%CI -1.30至-0.49);新生儿抗生素使用:阿奇霉素组6.2% vs 安慰剂组7.8%;RD -1.58(95%CI -2.49至-0.67)。
- 产妇乳腺炎发生率:阿奇霉素组0.3% vs 安慰剂组0.5%;RD -0.24(95%CI -0.47至-0.01);产褥热:阿奇霉素组0.1% vs 安慰剂组0.3%;RD -0.19(95%CI -0.36至-0.01)。
临床怎么用
- 作者结论指出,产时口服阿奇霉素未降低新生儿脓毒症或死亡率,这些结果不支持常规产时口服阿奇霉素用于该目的。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Neonatal sepsis is a leading cause of neonatal mortality. New interventions are needed to decrease neonatal sepsis and mortality in regions with highest burden. OBJECTIVE: To evaluate the efficacy of intrapartum azithromycin to reduce neonatal sepsis or mortality, as well as neonatal and maternal infections. DESIGN, SETTING, AND PARTICIPANTS: This double-blind, placebo-controlled, randomized clinical trial enrolled and followed up birthing parents and their infants at 10 health facilities in The Gambia and Burkina Faso, West Africa, between October 2017 and May 2021. INTERVENTIONS: Participants were assigned at random to receive oral azithromycin (2 g) or placebo (ratio 1:1) during labor. MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of neonatal sepsis or mortality, with the former defined based on microbiologic or clinical criteria. Secondary outcomes were neonatal infections (skin, umbilical, eye and ear infections), malaria, and fever; postpartum infections (puerperal sepsis, mastitis), fever, and malaria; and use of antibiotics during 4-week follow-up. RESULTS: The trial randomized 11 983 persons in labor (median age, 29.9 years). Overall, 225 newborns (1.9% of 11 783 live births) met the primary end point. The incidence of neonatal mortality or sepsis was similar in the azithromycin and placebo groups (2.0% [115/5889] vs 1.9% [110/5894]; risk difference [RD], 0.09 [95% CI, -0.39 to 0.57]), as was the incidence of neonatal mortality (0.8% vs 0.8%; RD, 0.04 [95% CI, -0.27 to 0.35]) and neonatal sepsis (1.3% vs 1.3%; RD, 0.02 [95% CI, -0.38 to 0.43]). Newborns in the azithromycin group compared with the placebo group had lower incidence of skin infections (0.8% vs 1.7%; RD, -0.90 [95% CI, -1.30 to -0.49]) and need for antibiotics (6.2% vs 7.8%; RD, -1.58 [95% CI, -2.49 to -0.67]). Postpartum parents in the azithromycin group had lower incidence of mastitis (0.3% vs 0.5%; RD, -0.24 [95% CI, -0.47 to -0.01]) and puerperal fever (0.1% vs 0.3%; RD, -0.19 [95% CI, -0.36 to -0.01]). CONCLUSIONS AND RELEVANCE: Azithromycin administered orally during labor did not reduce neonatal sepsis or mortality. These results do not support routine introduction of oral intrapartum azithromycin for this purpose. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03199547.
引用
- Roca A, Camara B, Bognini JD, et al. Effect of Intrapartum Azithromycin vs Placebo on Neonatal Sepsis and Death: A Randomized Clinical Trial. JAMA. 2023. PMID: 36881034. doi:10.1001/jama.2022.24388
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。